News | Heart Failure | January 23, 2024

Sequana Medical Announces DSMB Approval to Start Randomized MOJAVE Cohort

Data from non-randomized cohort confirms dramatic improvement in diuretic response and at least 95% reduction in loop diuretic requirements up to almost four months after last DSR therapy 

Data from non-randomized cohort confirms dramatic improvement in diuretic response and at least 95% reduction in loop diuretic requirements up to almost four months after last DSR therapy

Getty Images


January 23, 2024 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announced that an independent Data and Safety Monitoring Board (DSMB) approved the start of the randomized cohort in MOJAVE, the US Phase 1/2a study of DSR 2.0 for treatment of patients with diuretic-resistant heart failure, following review of the safety data reported from the non-randomized cohort. 

Follow-up data from the three patients in the non-randomized cohort confirm the durable improvement in their cardio-renal health and support DSR’s mechanism of action as breaking the vicious cycle of cardiorenal syndrome. 

The randomized controlled cohort will enroll up to 30 additional patients across different centers in the US, with up to 20 patients treated with DSR 2.0 on top of optimized usual care for congestive heart failure for up to four weeks, and up to ten control patients treated with intravenous loop diuretics as part of maximized usual care for congestive heart failure. After the last DSR treatment, patients will be followed for a three-month safety follow-up period. The first patient is expected to be enrolled in Q1 2024 and interim data are planned for H2 2024. 

Dr. Oliver Gödje, Chief Medical Officer of Sequana Medical, commented: “We are delighted to announce the ongoing progress of our US MOJAVE study and look forward to enroll the first patient in the randomized cohort later this quarter. Building upon the strong data reported from the non-randomized MOJAVE cohort and our previous RED DESERT and SAHARA studies, we are confident about the clinical effectiveness of our DSR therapy compared to loop diuretics. We look forward to reporting interim data from the MOJAVE randomized cohort in the second half of this year to further demonstrate the potential of DSR as a disease-modifying heart failure drug therapy tackling cardiorenal syndrome.” 

Positive data from non-randomized cohort of MOJAVE study 

Data from the four-week DSR treatment period, as reported previouslyii

All three patients treated in the non-randomized cohort of the MOJAVE study had heart failure with preserved ejection fraction (HFpEF) and severe diuretic resistance at baseline (mean furosemide equivalent dose of 1,227 mg per day). At the start of the study treatment period, loop diuretics were withheld, and patients were treated with DSR 2.0 up to daily for four weeks, followed by a three-month safety follow-up period. 

Dramatic improvement in diuretic response and renal status: During the four-week DSR treatment period, all three patients maintained euvolemia without the need of loop diuretics. Their diuretic responseiii nearly normalized with a mean increase of 324% in their six-hour urinary sodium excretion post-treatment vs baseline. There was a broad improvement in their kidney function with a a mean improvement in eGFRiv of 47% and blood urea nitrogenv of 57% post-treatment vs baseline. 

Updated data from the three-month safety follow-up period: 

Loop diuretics virtually eliminated vs. baseline: Two patients have completed the three-month safety follow-up period and one patient is still in the follow-up period. The need for loop diuretics was dramatically reduced or even completely eliminated up to 15 weeks after the four-week DSR treatment period (see table below). 

chart

Improvement in renal parameters maintained: At the end of the three-month safety follow-up period, the diuretic response of the two patients who already completed the study remained normalized, with a similar high output in their six-hour urinary sodium excretion as compared to their dramatically improved diuretic response after the four-week DSR treatment period. Their kidney function also remained stable as measured by their improvement in eGFR and blood urea nitrogen. 

To date, no clinically relevant changes in serum sodium levels or progressive hyponatremia were observed and none of the patients needed to be hospitalized for congestion since the start of the study. Until today, there was only one serious adverse event of short-term hypertension at 12 weeks after the last DSR therapy, which was adjudicated as non-related to DSR therapy. Short-term hypertension is often seen in this very sick patient population. These data indicate that DSR 2.0 is safe and well tolerated as confirmed by the DSMB. 

For more information: www.sequanamedical.com 

References: 

i DSMB: Data Safety Monitoring Board
ii See press release of 29 November 2023
iii Diuretic response assessed by 6-hour excretion of sodium after IV administration of 40mg furosemide 

Related Mojave Study Content:    

Sequana Medical Announces Initial Positive Data from MOJAVE, a US Phase 1/2a Study of DSR 2.0 for Treatment of Heart Failure Through Breaking Vicious Cycle of Cardiorenal Syndrome  

Sequana Medical Announces First Patient Enrolled in MOJAVE   

Sequana Medical Announces FDA Clearance of IND Application for DSR 2.0 for Treatment of Congestive Heart Failure   

Sequana Medical Announces Submission of Investigational New Drug (IND) Application for DSR 2.0 for Treatment of Congestive Heart Failure 

Sequana Medical Announces Positive Data from Non-randomized Cohort in US Phase 1/2a MOJAVE Study of DSR 2.0 for Treatment of Heart Failure


Related Content

News | Cardiovascular Clinical Studies

February 26, 2024 — More than 6 million Americans live with heart failure, and about half have an enlarged left ...

Home February 26, 2024
Home
News | Cardiovascular Clinical Studies

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
Home
News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
Home
News | Cardiovascular Clinical Studies

December 14, 2023 — Published results of a large, national heart attack study show that patients with a life-threatening ...

Home December 14, 2023
Home
News | Cardiovascular Clinical Studies

December 11, 2023 — A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely ...

Home December 11, 2023
Home
News | Cardiovascular Clinical Studies

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

Home December 08, 2023
Home
Subscribe Now